Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 1/6 |
Soiken Holdings Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥122.00 |
52 Week High | JP¥293.00 |
52 Week Low | JP¥107.00 |
Beta | -0.0027 |
11 Month Change | -27.38% |
3 Month Change | -29.07% |
1 Year Change | -55.96% |
33 Year Change | -68.06% |
5 Year Change | -80.42% |
Change since IPO | -96.19% |
Recent News & Updates
Many Still Looking Away From Soiken Holdings Inc. (TSE:2385)
Aug 02A Piece Of The Puzzle Missing From Soiken Holdings Inc.'s (TSE:2385) Share Price
Apr 01Shareholder Returns
2385 | JP Personal Products | JP Market | |
---|---|---|---|
7D | -29.1% | -11.1% | -18.6% |
1Y | -56.0% | -15.0% | -3.7% |
Return vs Industry: 2385 underperformed the JP Personal Products industry which returned -15% over the past year.
Return vs Market: 2385 underperformed the JP Market which returned -3.7% over the past year.
Price Volatility
2385 volatility | |
---|---|
2385 Average Weekly Movement | 9.0% |
Personal Products Industry Average Movement | 4.7% |
Market Average Movement | 5.6% |
10% most volatile stocks in JP Market | 9.0% |
10% least volatile stocks in JP Market | 3.0% |
Stable Share Price: 2385's share price has been volatile over the past 3 months.
Volatility Over Time: 2385's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 98 | Kentaro Ishigami | www.soiken.com |
Soiken Holdings Inc. engages in the development of biomarkers in Japan. The company is involved in the development and sale of cosmetics and dietary supplements comprising imidapeptides; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for pharmaceutical clinical research and epidemiology studies; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes.
Soiken Holdings Inc. Fundamentals Summary
2385 fundamental statistics | |
---|---|
Market cap | JP¥3.19b |
Earnings (TTM) | -JP¥619.00m |
Revenue (TTM) | JP¥5.33b |
0.6x
P/S Ratio-5.2x
P/E RatioIs 2385 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2385 income statement (TTM) | |
---|---|
Revenue | JP¥5.33b |
Cost of Revenue | JP¥2.84b |
Gross Profit | JP¥2.49b |
Other Expenses | JP¥3.11b |
Earnings | -JP¥619.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 15, 2024
Earnings per share (EPS) | -23.66 |
Gross Margin | 46.76% |
Net Profit Margin | -11.60% |
Debt/Equity Ratio | 0% |
How did 2385 perform over the long term?
See historical performance and comparison